tiprankstipranks
Advertisement
Advertisement

ARGX Stock Latest News

Argenx Completes Key CIDP Switch Study, Setting Up Next Steps for Efgartigimod
Company AnnouncementsArgenx Completes Key CIDP Switch Study, Setting Up Next Steps for Efgartigimod
4d ago
ARGX
Argenx price target lowered to $1,014 from $1,060 at Oppenheimer
PremiumThe Fly
Argenx price target lowered to $1,014 from $1,060 at Oppenheimer
8d ago
ARGX
Argenx added to European Conviction List at Goldman Sachs
PremiumThe Fly
Argenx added to European Conviction List at Goldman Sachs
9d ago
ARGX
Argenx Sets May 6, 2026 AGM and Unveils Board Changes as Jim Daly Retires
PremiumCompany Announcements
Argenx Sets May 6, 2026 AGM and Unveils Board Changes as Jim Daly Retires
21d ago
6K
ARGX
Argenx Files 2025 Annual Report and Links Dutch Filing to U.S. Registrations
PremiumCompany Announcements
Argenx Files 2025 Annual Report and Links Dutch Filing to U.S. Registrations
22d ago
6K
ARGX
Argenx Halts Phase 3 Thyroid Eye Disease Trial: Clinical Setback With Focused Market Impact
PremiumCompany AnnouncementsArgenx Halts Phase 3 Thyroid Eye Disease Trial: Clinical Setback With Focused Market Impact
25d ago
ARGX
Argenx Ends Phase 3 Thyroid Eye Disease Trial, Resetting Expectations for Efgartigimod
Premium
Company Announcements
Argenx Ends Phase 3 Thyroid Eye Disease Trial, Resetting Expectations for Efgartigimod
25d ago
ARGX
Argenx’s Long‑Term ITP Study Reaches Completion, Sharpening the Outlook for Efgartigimod
Premium
Company Announcements
Argenx’s Long‑Term ITP Study Reaches Completion, Sharpening the Outlook for Efgartigimod
25d ago
ARGX
Argenx upgraded to Buy from Hold at Deutsche Bank
PremiumThe Fly
Argenx upgraded to Buy from Hold at Deutsche Bank
1M ago
ARGX
Deutsche Bank upgrades Argenx on Vyvgart momentum, less-demanding valuation
PremiumThe Fly
Deutsche Bank upgrades Argenx on Vyvgart momentum, less-demanding valuation
1M ago
ARGX
Argenx Opens Phase 1 Safety Trial for ARGX-124, Expanding Its Pipeline Potential
PremiumCompany Announcements
Argenx Opens Phase 1 Safety Trial for ARGX-124, Expanding Its Pipeline Potential
1M ago
ARGX
Argenx Unveils New VYVGART and Neurology Pipeline Data Ahead of 2026 AAN Meeting
PremiumCompany Announcements
Argenx Unveils New VYVGART and Neurology Pipeline Data Ahead of 2026 AAN Meeting
1M ago
6K
ARGX
Argenx Earnings Call Highlights Explosive Growth, Ocular Win
PremiumCompany AnnouncementsArgenx Earnings Call Highlights Explosive Growth, Ocular Win
1M ago
ARGX
Argenx price target lowered to $890 from $925 at RBC Capital
Premium
The Fly
Argenx price target lowered to $890 from $925 at RBC Capital
1M ago
ARGX
Argenx price target lowered to $890 from $925 at RBC Capital
Premium
The Fly
Argenx price target lowered to $890 from $925 at RBC Capital
1M ago
ARGX
Argenx price target raised to $867 from $858 at Baird
PremiumThe Fly
Argenx price target raised to $867 from $858 at Baird
1M ago
ARGX
Argenx price target lowered to $1,120 from $1,160 at Guggenheim
PremiumThe Fly
Argenx price target lowered to $1,120 from $1,160 at Guggenheim
1M ago
ARGX
Argenx price target lowered to $1,247 from $1,317 at Wells Fargo
PremiumThe Fly
Argenx price target lowered to $1,247 from $1,317 at Wells Fargo
1M ago
ARGX
Argenx price target raised to $940 from $915 at H.C. Wainwright
PremiumThe Fly
Argenx price target raised to $940 from $915 at H.C. Wainwright
1M ago
ARGX
Argenx price target raised to $944 from $925 at Citizens
PremiumThe FlyArgenx price target raised to $944 from $925 at Citizens
1M ago
ARGX
Argenx price target lowered to $1,227 from $1,248 at Stifel
Premium
The Fly
Argenx price target lowered to $1,227 from $1,248 at Stifel
1M ago
ARGX
Vyvgart’s Strengthening MG Franchise and Pipeline Catalysts Support Buy Rating on Argenx
Premium
Ratings
Vyvgart’s Strengthening MG Franchise and Pipeline Catalysts Support Buy Rating on Argenx
1M ago
ARGX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >